FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For period ending May 2009
GlaxoSmithKline plc
(Name of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F
Form 20-F x Form 40-F
--
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes No x
--
GlaxoSmithKline plc - Result of AGM
GlaxoSmithKline (GSK) announces that at its Annual General Meeting today, all resolutions, including those electing and re-electing Board members, were passed by shareholders.
GlaxoSmithKline Annual General
Meeting Poll Results
The following table shows the votes
cast for each resolution:
|
Resolution |
Total votes for* |
% |
Total votes against |
% |
Total votes cast |
Votes withheld** |
|
|
1 |
Adoption of Financial Statements |
3,753,123,915 |
98.71 |
49,078,100 |
1.29 |
3,802,202,015 |
11,386,486 |
|
2 |
Approval of the Remuneration Report |
3,697,894,692 |
97.40 |
98,521,629 |
2.60 |
3,796,416,321 |
17,172,180 |
|
3 |
Election of James Murdoch |
3,757,009,509 |
99.43 |
21,384,326 |
0.57 |
3,778,393,835 |
35,194,666 |
|
4 |
Re-election of Larry Culp |
3,793,634,452 |
99.65 |
13,335,747 |
0.35 |
3,806,970,199 |
6,618,302 |
|
5 |
Re-election of Sir Crispin Davis |
3,792,927,536 |
99.63 |
14,128,576 |
0.37 |
3,807,056,112 |
6,532,389 |
|
6 |
Re-election of Dr Moncef Slaoui |
3,745,211,760 |
98.65 |
51,318,902 |
1.35 |
3,796,530,662 |
17,057,839 |
|
7 |
Re-election of Tom de Swaan |
3,741,563,392 |
98.28 |
65,347,381 |
1.72 |
3,806,910,773 |
6,677,727 |
|
8 |
Re-appointment of Auditors |
3,737,041,438 |
99.50 |
18,663,218 |
0.50 |
3,755,704,656 |
57,883,845 |
|
9 |
Remuneration of Auditors |
3,773,188,034 |
99.69 |
11,620,178 |
0.31 |
3,784,808,212 |
28,780,289 |
|
10 |
To authorise the company to make donations to Political Organisations & incur Political Expenditure |
3,701,721,594 |
97.53 |
93,559,528 |
2.47 |
3,795,281,122 |
18,307,379 |
|
11 |
Authority to allot shares |
3,605,902,539 |
96.41 |
134,189,208 |
3.59 |
3,740,091,747 |
73,496,753 |
|
12 |
Disapplication of pre-emption rights*** |
3,770,592,309 |
99.16 |
32,012,872 |
0.84 |
3,802,605,181 |
10,983,320 |
|
13 |
Authority for the Company to purchase its own shares *** |
3,748,071,427 |
98.56 |
54,890,465 |
1.44 |
3,802,961,892 |
10,626,609 |
|
14 |
Exemption from statement of senior statutory auditor’s name |
3,787,552,173 |
99.66 |
12,766,383 |
0.34 |
3,800,318,556 |
13,269,945 |
|
15 |
Reduced notice of a general meeting other than an AGM *** |
3,669,136,339 |
96.39 |
137,612,154 |
3.61 |
3,806,748,493 |
6,840,007 |
|
16 |
Adoption of the GSK 2009 Performance Share Plan |
3,704,014,846 |
97.60 |
91,201,480 |
2.40 |
3,795,216,326 |
18,372,175 |
|
17 |
Adoption of the GSK 2009 Share Option Plan |
3,690,525,851 |
98.50 |
56,305,534 |
1.50 |
3,746,831,385 |
66,757,116 |
|
18 |
Adoption of the GSK 2009 Deferred Annual Bonus Plan |
3,721,471,866 |
98.00 |
76,062,571 |
2.00 |
3,797,534,437 |
16,054,064 |
Notes:
* Includes discretionary votes.
** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.
*** Indicates Special Resolutions requiring a 75% majority
The following table provides further relevant information:
|
GlaxoSmithKline's |
GlaxoSmithKline's |
|
|
Issued share capital |
5,188,385,638 |
5,352,175,102 |
|
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares) |
73.50% |
73.78% |
|
Total shareholder population |
170,054 |
172,581 |
|
Total number of proxies lodged |
10,580 |
12,896 |
|
% of shareholders who lodged proxies |
6.22% |
7.47% |
|
Number of shareholders, corporate representatives and proxies who attended the AGM |
276 |
266 |
S M Bicknell
Company Secretary
20 May 2009
These results will shortly be available
on the Company's website
www.gsk.com
.
Enquiries:
|
UK Media enquiries: |
Philip Thomson |
(020) 8047 5502 |
|
David Outhwaite |
(020) 8047 5502 |
|
|
Stephen Rea |
(020) 8047 5502 |
|
|
US Media enquiries: |
Nancy Pekarek |
(919) 483 2839 |
|
Mary Anne Rhyne |
(919) 483 2839 |
|
|
Kevin Colgan |
(919) 483 2839 |
|
|
Sarah Alspach |
(919) 483 2839 |
|
|
European Analyst/Investor enquiries: |
David Mawdsley |
(020) 8047 5564 |
|
Sally Ferguson |
(020) 8047 5543 |
|
|
Gary Davies |
(020) 8047 5503 |
|
|
US Analyst/ Investor enquiries: |
Tom Curry |
(215) 751 5419 |
|
Jen Hill Baxter |
(215) 751 7002 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorised.
GlaxoSmithKline plc
(Registrant)
Date: May 20, 2009
By: VICTORIA WHYTE
------------------
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc